TCM
NVCR icon

Tradewinds Capital Management’s NovoCure NVCR Stock Holding History

Tradewinds Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-35
Closed -$566 – 513
2023
Q3 		$566 Hold
35
– – ﹤0.01% 422
2023
Q2 		$1.45K Hold
35
– – ﹤0.01% 354
2023
Q1 		$2.1K Hold
35
– – ﹤0.01% 333
2022
Q4 		$2.57K Hold
35
– – ﹤0.01% 345
2022
Q3 		$3K Hold
35
– – ﹤0.01% 307
2022
Q2 		$2K Hold
35
– – ﹤0.01% 345
2022
Q1 		$3K Hold
35
– – ﹤0.01% 629
2021
Q4 		$3K Buy
+35
New +$3.51K ﹤0.01% 641

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tradewinds Capital Management's NVCR Position: Q4 2023 in Review

Tradewinds Capital Management sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 35 shares — an estimated $566 sold.

Tradewinds Capital Management first reported a position in NVCR in Q4 2021 and held it in 8 quarters. The position peaked at $3K in Q3 2022. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

  • Tradewinds Capital Management reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
  • Tradewinds Capital Management sold 35 NovoCure shares in Q4 2023, an estimated $566.
  • Tradewinds Capital Management first reported a position in NovoCure in Q4 2021 and held it in 8 quarters.
  • Tradewinds Capital Management's NovoCure position peaked at $3K in Q3 2022.
  • 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Tradewinds Capital Management's 13F filing for Q4 2023, filed 1 Feb 2024.